CCCC ▲ +0.7% - C4 Therapeutics, Inc.
$CCCC - C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
25-SEP-2026 07:00 AM ET
Share this post
More filings for $CCCC
CCCC ▲ +2.4% - C4 Therapeutics, Inc.Sep 3, 2026CCCC - C4 Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026CCCC - C4 Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026CCCC - C4 Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026CCCC - C4 Therapeutics, Inc. - SEC Filing Update (12-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 12, 2026$CCCC SEC Filing Update (27-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 27, 2026
View full $CCCC filing history →💬 Comments
Loading comments…
Leave a comment